Anzeige
Mehr »
Login
Mittwoch, 08.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Rio Tintos Muster: Erst die Investition, dann die Milliarden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DK1X | ISIN: US87151X1019 | Ticker-Symbol:
NASDAQ
07.01.25
21:59 Uhr
25,635 US-Dollar
0,000
0,00 %
Branche
Maschinenbau
Aktienmarkt
Sonstige
1-Jahres-Chart
SYMBOTIC INC Chart 1 Jahr
5-Tage-Chart
SYMBOTIC INC 5-Tage-Chart
GlobeNewswire (Europe)
60 Leser
Artikel bewerten:
(0)

Symbotic Inc.: Symbotic Names Dr. James Kuffner as Chief Technology Officer

Finanznachrichten News

WILMINGTON, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, today announced the appointment of Dr. James Kuffner as Chief Technology Officer (CTO), effective January 1, 2025, in line with the retirement of George Dramalis, Symbotic's former CTO. In his new role, Kuffner will be responsible for continuing to advance Symbotic's technologies and solutions to drive Symbotic's strategic long-term growth.

"James has more than 30 years of leadership experience in robotics. He has helped forge groundbreaking technological advances at Toyota, Google and Carnegie Mellon University's Robotics Institute," said Rick Cohen, Chairman of the Board and Chief Executive Officer.

As the author of 125 publications and 40 patents in 3D graphics, robotics and autonomous vehicles, James is most notably known as the co-inventor of the Rapidly Exploring Random Tree (RRT) algorithm for robot motion planning. James joins Symbotic from Toyota Motor Corporation, where he held several leadership roles during his long tenure. Most recently, he was a Senior Fellow in charge of the company's Software Development Center, after serving as Toyota's Chief Digital Officer and Member of the Board.

"James is a visionary leader whose cutting-edge research and development have accelerated the world's technological solutions," continued Cohen. "We are excited to welcome him to Symbotic and look forward to his development of innovative solutions that will unlock Symbotic's next phase of growth."

ABOUT SYMBOTIC

Symbotic is an automation technology leader reimagining the supply chain with its end-to-end, A.I.-powered robotic and software platform. Symbotic reinvents the warehouse as a strategic asset for the world's largest retail, wholesale, and food & beverage companies. Applying next-generation technology, high-density storage and machine learning to solve today's complex distribution challenges, Symbotic enables companies to move goods with unmatched speed, agility, accuracy and efficiency. As the backbone of commerce, Symbotic transforms the flow of goods and the economics of the supply chain for its customers. For more information, visit www.symbotic.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements about the transition of Dr. Kuffner to the role of Chief Technology Officer and Symbotic's expectations or predictions of future financial or business performance or conditions. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. Certain of these risks are identified and discussed in Symbotic's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on December 4, 2024. These forward-looking statements are expressed in good faith, and Symbotic believes there is a reasonable basis for them. However, there can be no assurance that the events, results or trends identified in these forward-looking statements will occur or be achieved. Forward-looking statements speak only as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. Symbotic is not under any obligation, and expressly disclaims any obligation to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Readers should carefully review the statements set forth in the reports that Symbotic has filed or will file from time to time with the SEC.

INVESTOR RELATIONS CONTACT

Charlie Anderson
Vice President, Investor Relations & Corporate Development
ir@symbotic.com

MEDIA INQUIRIES

mediainquiry@symbotic.com


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.